chronic obstructive pulmonary disease (COPD) may coexist with type 2 diabetes mellitus (T2DM). patients with COPD have an increased risk of developing T2DM compared with a control but, on the other side, hyperglycaemia and DM have been associated with reduced predicted levels of lung function. the mechanistic relationships between these two diseases are complicated, multifaceted, and little understood, yet they can impact treatment strategy. the potential risks and benefits for patients with T2DM treated with pulmonary drugs and the potential pulmonary risks and benefits for patients with COPD when taking antidiabetic drugs should always be considered. the interaction between the presence and/or treatment of COPD, risk of infection, presence and/or treatment of T2DM and risk of acute exacerbations of COPD (AECOPDs) can be represented as a vicious circle; however, several strategies may help to break this circle. the most effective approach to simultaneously treating T2DM and COPD is to interfere with the shared inflammatory substrate, thus targeting both lung inflammation (COPD) and vascular inflammation (DM). In any case, it is always crucial to establish glycaemic management since the reduction in lung function found in people with diabetes might decrease the threshold for clinical manifestations of COPD. In this article, we examine possible connections between COPD and T2DM as well as pharmacological strategies that could focus on these connections.

Cazzola, M., Rogliani, P., Ora, J., Calzetta, L., Lauro, D., Matera, M.g. (2023). Hyperglycaemia and Chronic Obstructive Pulmonary Disease. DIAGNOSTICS, 13(21), 1-13 [10.3390/diagnostics13213362].

Hyperglycaemia and Chronic Obstructive Pulmonary Disease

Cazzola M.;Rogliani P.;Calzetta L.;Lauro D.;Matera M. G.
2023-01-01

Abstract

chronic obstructive pulmonary disease (COPD) may coexist with type 2 diabetes mellitus (T2DM). patients with COPD have an increased risk of developing T2DM compared with a control but, on the other side, hyperglycaemia and DM have been associated with reduced predicted levels of lung function. the mechanistic relationships between these two diseases are complicated, multifaceted, and little understood, yet they can impact treatment strategy. the potential risks and benefits for patients with T2DM treated with pulmonary drugs and the potential pulmonary risks and benefits for patients with COPD when taking antidiabetic drugs should always be considered. the interaction between the presence and/or treatment of COPD, risk of infection, presence and/or treatment of T2DM and risk of acute exacerbations of COPD (AECOPDs) can be represented as a vicious circle; however, several strategies may help to break this circle. the most effective approach to simultaneously treating T2DM and COPD is to interfere with the shared inflammatory substrate, thus targeting both lung inflammation (COPD) and vascular inflammation (DM). In any case, it is always crucial to establish glycaemic management since the reduction in lung function found in people with diabetes might decrease the threshold for clinical manifestations of COPD. In this article, we examine possible connections between COPD and T2DM as well as pharmacological strategies that could focus on these connections.
2023
Pubblicato
Rilevanza internazionale
Review
Esperti anonimi
Settore MED/10
English
chronic obstructive pulmonary disease
hyperglycaemia
lung function
pharmacological interferences
systemic inflammation
type 2 diabetes mellitus
Cazzola, M., Rogliani, P., Ora, J., Calzetta, L., Lauro, D., Matera, M.g. (2023). Hyperglycaemia and Chronic Obstructive Pulmonary Disease. DIAGNOSTICS, 13(21), 1-13 [10.3390/diagnostics13213362].
Cazzola, M; Rogliani, P; Ora, J; Calzetta, L; Lauro, D; Matera, Mg
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Hyperglycemia and Chronic Obstructive Pulmonary Disease .pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 314.13 kB
Formato Adobe PDF
314.13 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/374244
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact